1型糖尿病中不同CGM传感器GMI与HbA1c的一致性比较
本研究回顾性分析使用自动胰岛素输注的1型糖尿病成人真实世界数据,比较Dexcom、MiniMed和Abbott传感器下原始GMI及更新版uGMI与实验室HbA1c的一致性。结果显示各传感器组间平均绝对差异无显著统计学差异,GMI/uGMI表现一致。临床上出现有意义的差异时,应结合个体临床和实验室因素解读,而非归因于传感器厂商。
要点
- GMI/uGMI在不同CGM传感器组间表现一致,绝对差异无统计学显著差异。
- 方向性差异有统计学意义但幅度小,无临床重要性。
- GMI与HbA1c出现临床有意义差异时,应结合个体因素解读。
核心结论
- GMI/uGMI在Dexcom、MiniMed和Abbott传感器组间表现一致。
- GMI与HbA1c的临床有意义差异应结合个体临床和实验室因素解读,而非归因于传感器制造商。
研究设计与样本
- 回顾性分析使用自动胰岛素输注的1型糖尿病成人真实世界数据。
- 90天HbA1c前样本383例,28天HbA1c前样本375例。
- 采用ANCOVA校正变异系数和种族后评估传感器组间一致性。
主要发现
- 各传感器组90天校正均值,Δ(GMI-HbA1c):Dexcom 0.17%(95%CI 0.09–0.25),MiniMed −0.15%(95%CI −0.28至−0.02),Abbott −0.08%(95%CI −0.25至0.09)。
- Δ(uGMI-HbA1c):Dexcom 0.22%(95%CI 0.14–0.30),MiniMed −0.10%(95%CI −0.23至0.02),Abbott −0.02%(95%CI −0.19至0.15)。
- 方向性差异在所有传感器组均有统计学意义(p<0.001),但幅度小、无临床重要性。
- 平均绝对差异在传感器组间无显著差异:Δ(GMI-HbA1c) 0.42%–0.51%(p=0.353),Δ(uGMI-HbA1c) 0.41%–0.52%(p=0.221)。
临床怎么用
- GMI/uGMI可跨Dexcom、MiniMed和Abbott传感器一致使用,无需因传感器厂商调整解读。
- GMI与HbA1c出现临床有意义差异时,应结合个体临床和实验室因素综合判断。
局限性
- 回顾性真实世界数据可能存在选择偏倚和混杂因素。
- 仅纳入使用自动胰岛素输注的1型糖尿病成人,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims The continuous glucose monitoring (CGM)-derived glucose management indicator (GMI) is used for estimating glycated haemoglobin (HbA1c). This study assessed agreement between GMI—calculated using both original and updated (uGMI) models—and laboratory-measured HbA1c across Dexcom, MiniMed and Abbott sensors. Materials and Methods Real-world data from adults with type 1 diabetes using automated insulin delivery were retrospectively analysed. Δ(GMI-HbA1c) and Δ(uGMI-HbA1c) were evaluated over 90 days preceding HbA1c (n = 383) and over 28 days preceding HbA1c (n = 375). Agreement was measured as directional difference, indicating GMI overestimation or underestimation of HbA1c, and absolute difference, indicating magnitude of agreement between GMI and HbA1c. Agreement was assessed across sensor groups using ANCOVA, adjusting for coefficient of variation and ethnicity. Results Although mean directional differences were statistically significant for Δ(GMI-HbA1c) and Δ(uGMI-HbA1c) across all sensor groups (p < 0.001), differences were small and not clinically important, 90-day adjusted means (95% CI)—Δ(GMI-HbA1c): Dexcom 0.17% (0.09, 0.25), MiniMed −0.15% (−0.28, −0.02), Abbott −0.08% (−0.25, 0.09); Δ(uGMI-HbA1c): Dexcom 0.22% (0.14, 0.30), MiniMed −0.10% (−0.23, 0.02), Abbott −0.02% (−0.19, 0.15). Mean absolute difference did not significantly differ across sensor groups—Δ(GMI-HbA1c): 0.42%–0.51% (p = 0.353), Δ(uGMI-HbA1c): 0.41%–0.52% (p = 0.221). Conclusions GMI/uGMI performed consistently across sensor groups. Where clinically meaningful discrepancies between GMI/uGMI and HbA1c arise, these warrant interpretation within the context of individual clinical and laboratory factors rather than attribution to sensor manufacturer, reinforcing the need for personalised use of GMI alongside HbA1c.
引用
- Diabetes, Obesity and Metabolism:A Comparative Analysis Between Original and Updated Glucose Management Indicator and Glycated Haemoglobin Across Continuous Glucose Monitoring Sensors in Type 1 Diabetes
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。